Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report.

ABSTRACT:

Background

Tocilizumab is a humanized monoclonal antibody that acts as an IL-6 receptor antagonist. Intravenous tocilizumab is considered an option for children with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis. In contrast, the potential of subcutaneous drug use with this indication is more controversial. Due to the decreased availability of intravenous tocilizumab during the COVID-19 pandemic, we started using the subcutaneous formulation of the drug in children with anti-TNF refractory uveitis. The study analyzes the serum concentration of tocilizumab and its clinical response in patients with anti-TNF refractory uveitis who started or switched to subcutaneous administration from intravenous use.

Methods

Five patients with non-infectious uveitis we

SUBMITTER: Burlo F 

PROVIDER: S-EPMC10496382 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature